… review board of the participating hospitals. Given the … -ritonavir, molnupiravir, or azvudine
treatment within 5 days … , and with no immunosuppression could significantly benefit …

… Molnupiravir Ribonucleoside analog of N-hydroxycytidine whose active form interferes with
RNA-… Although remdesivir resistance mutations have been reported in immunocompromised …

… treated at the outpatient clinic, of whom 420 were treated with SOT, 398 with N/R and 1788
with MOL. 10 patients (3.2%) who were treated … in a population of participants at high risk for …

… to severe disease, treatment with molnupiravir was associated … on the use of molnupiravir in
immunosuppressed patients, as … subgroup of immunosuppressed patients, molnupiravir was …

… hamsters, mice, immunodeficient mice implanted with human … ) seen in the three molnupiravir
treated groups. A significant … evaluation, 10 participants were given molnupiravir 200 mg …

… the different treatment options for immunocompromised … In the MOVe-OUT trial, molnupiravir
reduced the rate of … detected in immunocompetent control participants. Factors associated …

… second-line therapy (molnupiravir) reduces the prevalence of … , such as those who are
immunocompromised (14). Two … /ritonavir treatment among immunocompromised subjects ¶¶ and …

… Immunosuppressed patients with COVID-19 whose … appropriate treatment options are
available, molnupiravir may be … Study participants presented with risk factors for severe COVID-…

… Participants … period based on characteristics such as immunosuppression, we categorized
vaccination as … Of note, the molnupiravir-treated patients in our study had a higher number of …

… The MITT population comprised 763 participants randomized to molnupiravir and 764 to
placebo; 83.6% had anti-… Of note, treatment of COVID-19 with molnupiravir was prohibited in trial …